APVO
Aptevo Therapeutics Inc.
There isn't enough reported data to score APVO yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
APVO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
APVO's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
APVO PE Valuation
APVO has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
APVO Forward outlook
There aren't enough analyst estimates for APVO to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
APVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$1,347,984.00 | -280% |
| Q2 2023 | -$1,934,064.00 | -344% |
| Q1 2023 | $2,057,140.80 | +$5,561,899.20 |
| Q4 2022 | $920,145.60 | +$4,477,651.20 |
| Q3 2022 | $750,182.40 | +$4,700,361.60 |
| Q2 2022 | $791,208.00 | +$5,134,060.80 |
| Q1 2022 | -$3,504,758.40 | +$1,043,222.40 |
| Q4 2021 | -$3,557,505.60 | -$492,307.20 |
HIMS has the stronger earnings trend. Trailing diluted EPS is down 280% for APVO versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
APVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2022 | $3.1M | +29% |
| Q4 2021 | $3.7M | +54% |
| Q3 2021 | $3.1M | +112% |
| Q2 2021 | $3.1M | +558% |
| Q4 2020 | $2.4M | -74% |
| Q3 2020 | $1.5M | -84% |
HIMS has the stronger quarterly revenue trend. Revenue is down 100% for APVO versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2022 | -180% | +104 points |
| Q4 2021 | -110% | +177 points |
| Q3 2021 | -153% | +274 points |
| Q2 2021 | -184% | N/A |
| Q1 2021 | -285% | N/A |
| Q4 2020 | -287% | -202 points |
| Q3 2020 | -427% | -310 points |
| Q4 2019 | -85% | N/A |
APVO's operating margin was −180% last quarter, up 104 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
APVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.5M | +$1.6M |
| Q1 2026 | -$8M | -$1.4M |
| Q4 2025 | -$5.2M | +$523K |
| Q3 2025 | -$6.7M | -$1.5M |
| Q2 2025 | -$7.1M | -$940K |
| Q1 2025 | -$6.6M | +$76K |
| Q1 2024 | -$6.7M | -246% |
| Q4 2022 | -$5.9M | -$1.9M |
APVO has burned cash in almost every quarter: −$25M over the past year, against −$25M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over APVO on cash generation, producing positive trailing cash flow while its opponent burns cash.
APVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +136K shares |
| 1 year | +29433% | +1.2M shares |
| 3 years | +13292833% | +1.2M shares |
| 5 years | +19939300% | +1.2M shares |
APVO has 1M diluted shares, up 29433% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over APVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
APVO Net Leverage
APVO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
APVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.9 | Oversold |
| Stochastic | 2.8 | Oversold |
APVO's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
APVO PE vs Healthcare Sector
| Metric | APVO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
APVO has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
APVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.49 | 56% below |
| 20 week MA | $2.56 | 74% below |
| 50 week MA | $5.60 | 88% below |
| 100 week MA | $233.4 | 100% below |
| 200 week MA | $171,716.8 | 100% below |
APVO is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
APVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4,849,225.9 | $20,747,232.0 | +328% |
| 2021 | $20,747,232.0 | $4,612,449.6 | -78% |
| 2022 | $4,612,449.6 | $1,213,185.6 | -74% |
| 2023 | $1,213,185.6 | $106,080.5 | -91% |
| 2024 | $106,080.5 | $1,731.6 | -98% |
| 2025 | $1,731.6 | $10.9 | -99% |
| 2026 YTD | $10.9 | $0.66 | -94% |
APVO has finished five years in a row lower, and it's down 94% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over APVO on returns for 2026, with the stronger performance.